Related Experiment Video
Updated: Jul 25, 2026

09:01
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
Local gene delivery to the vessel wall
1Division of Cardiovascular Research, St Elizabeth's Medical Center, Boston, MA 02135, USA.
Acta Physiologica Scandinavica
|October 27, 2001
Summary
This review covers vascular gene therapy delivery methods proven in animal models to prevent restenosis after procedures. It examines current vector and gene transfer techniques for vessel walls, highlighting efficiency as key to success.
Area of Science:
- Cardiovascular Research
- Gene Therapy
- Vascular Biology
Background:
- Post-interventional restenosis remains a significant clinical challenge.
- Gene therapy offers a promising approach to prevent vascular remodeling.
- Effective delivery of genetic material to the vessel wall is crucial.
Purpose of the Study:
- To review current delivery strategies for vascular gene therapy.
- To focus on methods demonstrated to limit post-interventional restenosis in vivo.
- To assess the efficacy of existing vectors and gene transfer techniques.
Main Methods:
- Literature review of studies utilizing in vivo model systems.
- Analysis of delivery strategies for vascular gene therapy.
- Evaluation of vector efficacy and gene transfer methods.
Main Results:
- Several delivery strategies show potential in limiting restenosis in animal models.
- Current vectors and methods vary in their efficiency for gene transfer to the vessel wall.
- In vivo demonstration of efficacy is a critical factor.
Conclusions:
- Delivery strategy is paramount for successful vascular gene therapy.
- Further optimization of vectors and methods is needed to improve efficiency.
- In vivo validation is essential for clinical translation.
Related Concept Videos
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

